<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>POLIFARMATSIYA VA DORI–DORI O‘ZARO TA’SIRLARI: KLINIK XAVFLAR, PROFILAKTIKA VA DORI KO‘RIB CHIQISH (MEDICATION REVIEW) ALGORITMLARI</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Gulnoza</mods:namePart><mods:namePart type="family">Qurbonova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Maxfirat</mods:namePart><mods:namePart type="family">Kibriyeva</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Polifarmatsiya (odatda 5 va undan ortiq dori vositasini bir vaqtda qabul qilish) ko‘p kasallikli bemorlarda klinik natijalarni yaxshilashi mumkin, biroq u dori–dori o‘zaro ta’sirlari (DDI), nojo‘ya dori reaksiyalari, dori xatolari, adherens pasayishi hamda davolash xarajatlarining ortishi bilan bog‘liq xavflarni sezilarli oshiradi. Ayniqsa, keksa yosh, buyrak/jigar funksiyasi pasayishi, tor terapevtik oraliqli preparatlar (antikoagulyantlar, antiaritmiklar va boshqalar) qabul qilinishi hamda OTC/fitopreparatlar qo‘shilishi klinik ahamiyatli DDI ehtimolini kuchaytiradi. Ushbu tahliliy maqolada polifarmatsiyaning asosiy sabablari va “o‘rinli” hamda “muammoli” polifarmatsiya tushunchalari yoritiladi; farmakokinetik (CYP fermentlari, P-gp, absorbsiya va eliminatsiya o‘zgarishi) va farmakodinamik (qon ketish, giperkalemiya, sedatsiya/yiqilish, QT oralig‘i uzayishi) o‘zaro ta’sir mexanizmlari tizimlashtiriladi. Shuningdek, xavfni kamaytirish uchun dori yarashtirish (medication reconciliation), strukturali dori ko‘rib chiqish (medication review), skrining mezonlari (Beers, STOPP/START) hamda “Avoid–Adjust–Monitor” tamoyiliga asoslangan amaliy boshqaruv algoritmi taklif etiladi. Maqola yakunida individual depreskribing yondashuvi va monitoring orqali polifarmatsiya xavfsizligini oshirish bo‘yicha tavsiyalar beriladi</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-02-14</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>South Aral Region Medical Journal</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>